[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Guideline for the treatment of Hansen's disease in Japan.

  • Goto Masamichi
    Department of Pathology, Faculty of Medicine, Kagoshima University ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Ishida Yutaka
    International Medical Cooperation Bureau, International Medical Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Gidoh Masaichi
    National Institute for Infectious Disease, Leprosy Research Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Nagao Eiji
    National Hansen's Disease Sanatorium, Ohshima-Seishoen ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Namisato Masako
    National Hansen's Disease Sanatorium, Tama-Zenshoen ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Ishii Norihisa
    National Institute for Infectious Disease, Leprosy Research Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
  • Ozaki Motoaki
    Hyogo Prefectural Amagasaki Hospital ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association

Bibliographic Information

Other Title
  • ハンセン病治療指針

Search this article

Abstract

ad hoc committee of Japanese Leprosy Association recommends standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 1997). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) ≥3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (A-1) When satisfactory decrease of BI (BI value decrease≥2 steps, or final BI<3) is obtained after completion of 2 years MDT/MB, maintenance therapy by dapsone and clofazimine is recommended until BI negativity and loss of active lesions. (A-2) When BI decrease is not satisfactory (BI value decrease <2 steps, or final BI≥3), MDT/MB should be continued until BI negativity and loss of active lesions. (B) For MB with BI<3 or fresh MB (less than 6 months after the onset of the disease) with BI≥3, 1 year treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (B-1) When BI become negative and active lesion is lost within one year, no maintenance therapy is necessary. (B-2) When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.

Journal

Citations (15)*help

See more

References(34)*help

See more

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Details

Report a problem

Back to top